Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705254 | 0.99 | HPGDS (0.36) | HPGDSBACE1CTSDUSP30PARP1 | |
| SCHEMBL4286693 | 0.93 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL4282962 | 0.92 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL13705256 | 0.91 | EGFR (0.35) | HPGDSBACE1CTSDUSP30PARP1 | |
| SCHEMBL13705307 | 0.91 | USP30 (0.34) | HPGDSUSP30PARP1ACKR3APLNR | |
| SCHEMBL13705261 | 0.91 | HPGDS (0.34) | HPGDSBACE1CTSDUSP30PARP1 | |
| SCHEMBL13705262 | 0.90 | HPGDS (0.33) | HPGDSBACE1CTSDUSP30ACKR3 | |
| SCHEMBL13705145 | 0.89 | ABHD6 (0.42) | HPGDSUSP30PARP1PRMT5 | |
| SCHEMBL13705257 | 0.88 | USP30 (0.34) | HPGDSUSP30PARP1ACKR3CKS1B | |
| SCHEMBL13705312 | 0.88 | PRMT5 (0.36) | HPGDSBACE1CTSDUSP30PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HPGDS 1198/4885BACE1 1003/4885CTSD 1918/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HPGDS 1198/4885BACE1 1003/4885CTSD 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.